论文部分内容阅读
目的探讨硫酸镁联合拉贝洛尔治疗子痫前期的临床效果,观察其对妊娠结局的影响,为临床治疗子痫前期提供依据。方法随机选择2014年1月~2015年1月某院子痫前期孕妇96例,随机分为治疗组(48例)和对照组(48例),对照组孕妇给予硫酸镁等常规治疗,治疗组在对照组治疗基础上应用拉贝洛尔治疗。主要评估两组孕妇治疗前后收缩压、舒张压、24 h蛋白尿变化,并观察两组孕妇妊娠结局。结果治疗组患者治疗后平均收缩压、舒张压和24 h蛋白尿分别为(130.28±10.77)mm Hg、(83.21±2.90)mm Hg和(1.02±0.21)g,均低于对照组治疗后,两组治疗后均低于治疗前,差异具有统计学意义(P<0.05)。治疗组孕产妇不良妊娠结局合计为6.25%,低于对照组18.75%,差异具有统计学意义(P<0.05)。两组终止妊娠结果比较,差异无统计学意义(P>0.05)。治疗组终止妊娠孕周为(35.72±0.83)周,高于对照组(34.18±0.94)周,差异具有统计学意义(P<0.05)。结论硫酸镁联合拉贝洛尔治疗子痫前期孕妇能够显著降低其血压,减少尿蛋白,改善妊娠结局,值得临床推广应用。
Objective To investigate the clinical effect of magnesium sulfate combined with labetalol in the treatment of preeclampsia and to observe the effect of magnesium sulfate on the outcome of pregnancy and provide the basis for the clinical treatment of preeclampsia. Methods Ninety-six pregnant women with preeclampsia in a hospital from January 2014 to January 2015 were randomly divided into treatment group (48 cases) and control group (48 cases). Pregnant women in the control group were given conventional therapy such as magnesium sulfate, Control group based on the application of labetalol treatment. The main assessment before and after treatment of two groups of systolic blood pressure, diastolic blood pressure, 24 h proteinuria, and observed the pregnancy outcome of two groups of pregnant women. Results After treatment, the average systolic blood pressure, diastolic blood pressure and 24 h proteinuria in the treatment group were (130.28 ± 10.77) mm Hg, (83.21 ± 2.90) mm Hg and (1.02 ± 0.21) g, respectively, which were lower than those in the control group Both groups were lower than before treatment, the difference was statistically significant (P <0.05). Treatment group adverse pregnancy outcomes of maternal total 6.25%, lower than the control group 18.75%, the difference was statistically significant (P <0.05). Two groups of termination of pregnancy results, the difference was not statistically significant (P> 0.05). The gestational age in the treatment group was (35.72 ± 0.83) weeks, which was higher than that in the control group (34.18 ± 0.94) weeks, the difference was statistically significant (P <0.05). Conclusion Magnesium sulfate combined with labetalol in pregnant women with preeclampsia can significantly reduce their blood pressure, reduce urinary protein, improve pregnancy outcome, worthy of clinical application.